Regeneron Pharmaceuticals (REGN) Reports 84 Week Phase III Efficacy For FOP Treatment

Regeneron Pharmaceuticals (NasdaqGS:REGN) reported new Phase III OPTIMA data showing Pasatru maintained efficacy out to 84 weeks in adults with FOP. The 84 week results indicate Pasatru prevented new bone formation and cut disease flare ups in treated fibrodysplasia ossificans progressiva patients. Regeneron flagged ongoing regulatory filings in additional markets and a planned pediatric trial to extend Pasatru access to younger FOP patients. The fresh 84 week Pasatru OPTIMA data fits into a...